SCHEMBL4038398

SCHEMBL4038398

COc1ccc(-n2nc(Nc3ccc(Oc4ccccc4)cc3)nc2N)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 9/20 0.62
ALDH1A1 P00352 2/20 0.57
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
IMPDH2 P12268 1/20 0.50
AXL P30530 2/20 0.47
AURKA O14965 1/20 0.47
JAK2 O60674 1/20 0.47
KIT P10721 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
LMNA P02545 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
GAA P10253 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KCNH3 Q9ULD8 1/20 0.44
ABCB11 O95342 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4039213 0.92 FLT3 (0.64) FLT3ALDH1A1CA12CA1CA2
SCHEMBL4039312 0.91 FLT3 (0.62) FLT3ALDH1A1IMPDH2AXLKIT
SCHEMBL4043451 0.91 FLT3 (0.63) FLT3ALDH1A1CA1CA2IMPDH2
SCHEMBL4047489 0.83 FLT3 (0.74) FLT3ALDH1A1CA12CA1CA2
SCHEMBL12779223 0.83 FLT3 (0.53) FLT3ALDH1A1CA12CA1CA2
SCHEMBL4038418 0.82 FLT3 (0.65) FLT3ALDH1A1CA1CA2IMPDH2
SCHEMBL4038992 0.81 FLT3 (0.80) FLT3ALDH1A1CA12CA1CA2
SCHEMBL4040549 0.80 FLT3 (0.55) FLT3ALDH1A1IMPDH2AURKAJAK2
SCHEMBL4043648 0.79 FLT3 (0.60) FLT3ALDH1A1IMPDH2AXLKIT
SCHEMBL4039280 0.79 FLT3 (0.60) FLT3ALDH1A1IMPDH2AXLJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 FLT3 220/4885ALDH1A1 3235/4885CA12 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.